This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Looking at the potential of REL-1017 in treating Depression ahead of multiple Phase 3 readouts in 2022.


Who's the expert?

Institution: Private Practice, Los Gatos CA

  • Private practice Psychiatrist and former adjunct faculty in Psychiatry at the University of California at San Francisco and Stanford University.
  • Currently manages 50 patients with schizophrenia, 200 patients with depression, and 50 patients with bipolar disorder.
  • Research interest in schizophrenia and extensive industry collaboration, having served as a PI and as a member of an Advisory Board.

Interview Goal
This conversation will look at past data, some skepticism here that this hits the receptors it claims to hit, commercial potential, the abuse potential studies, mono vs combo, onset vs other clinical candidates, etc

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.